Do you have $ 10,000? Invest in these 3 stocks of coronavirus vaccines


The race for the coronavirus vaccine is far from over and investors still have plenty of time to benefit from ongoing clinical development and research activities. Even a relatively small investment in the right business could pay off a lot.

If you have $ 10,000 to invest today, rather than embarking on a single high-profile effort, consider spreading your funds across a handful of these promising coronavirus stocks so that your portfolio has a chance to grow even if one. individual vaccine project fails.

Image source: Getty Images.

Inovio Pharmaceuticals

Inovio Pharmaceuticals (NASDAQ: INO) stock has thrilled early investors by growing over 500% this year thanks to its DNA-based prophylactic project. Inovio’s vaccine still has a long way to go before it receives regulatory approval, but the company reported in late June that an astonishing 94% of its 40 Phase 1 trial subjects had an immune response against the new coronavirus. This is particularly exciting, because in preclinical animal trials Inovio’s candidate protected against infection very effectively, so similar results will mean he might be able to completely prevent infection in l ‘man.

Each round of positive results will strengthen the validity of Inovio’s DNA drug platform, sowing the seeds for future growth through further pipeline projects and new collaborations. Look for announcements of new manufacturing collaborations to get a read of what the company expects to be in a year. And remember that its coronavirus vaccine is just one interesting project among many in Inovio’s pipeline.


GlaxoSmithKline (NYSE: GSK) is the master of the coronavirus collaboration, benefiting from a myriad of research partnerships and joint development pacts with small biotechnologies like For biotechnology (NASDAQ: VIR) as well as major competitors like Sanofi (NASDAQ: SNY). While GlaxoSmithKline’s stock has yet to recover from the March crash, the company’s deep integrations with other vaccine developers leave it strongly positioned for future growth.

At the heart of GlaxoSmithKline’s coronavirus strategy is its adjuvant system to stimulate immune responses, which it says will reduce the total amount of prophylactic needed for an effective dose. Management aims to manufacture at least one billion doses of adjuvant by 2021, paving the way for dozens of additional collaborations, each of which would be a potential benefit to the company if successful. The company’s latest collaboration is with Medicago (TSX: MDG), a biotechnology that produces virus-like particles that GSK hopes to combine with its adjuvant to produce a highly potent – and very effective in terms of dose – vaccine. This is the second joint vaccine effort to use GSK’s adjuvant system, an earlier collaboration with Clover Biopharmaceuticals that began in June.

Be vigilant for direct investments or the acquisition of small collaborators, which would be a strong signal that GlaxoSmithKline considers these joint projects as a source of income in the long term.

SPY data by YCharts.


Modern (NASDAQ: ARNM) is one of the hottest stocks in biotech, thanks to its tremendous growth and early entry into the coronavirus prevention race. However, Moderna’s stock may be overvalued due to the early exuberance surrounding its coronavirus project, and biotech investors should be wary of the fact that it is highly prone to large intraday fluctuations depending on the business cycle. current events.

Nonetheless, its abbreviated clinical trial process moves quickly and with relatively few stumbling blocks; Moderna even launched its Phase 3 vaccine efficacy trial earlier this week. Based on preliminary data from his Phase 1 trials, the candidate did not cause any life-threatening side effects, and research subjects exhibited formidable antibody levels after vaccination, although he is still not clear whether they will be fully protected from infection.

Importantly, Moderna secured an additional $ 472 million in funding from the US government to support late-stage development, for a total of $ 955 million. This means that the main obstacles to the candidate’s success are their security and efficiency, rather than financial or business constraints. Future data disclosures and cash injections are additional growth opportunities, and it wouldn’t be too surprising if the company continues to grow rapidly throughout the year.


Please enter your comment!
Please enter your name here